EP1753425A4 - A therapeutic agent containing nicotinic acid or its derivatives as an effective ingredient for prevention and treatment of cancer - Google Patents

A therapeutic agent containing nicotinic acid or its derivatives as an effective ingredient for prevention and treatment of cancer

Info

Publication number
EP1753425A4
EP1753425A4 EP05764719A EP05764719A EP1753425A4 EP 1753425 A4 EP1753425 A4 EP 1753425A4 EP 05764719 A EP05764719 A EP 05764719A EP 05764719 A EP05764719 A EP 05764719A EP 1753425 A4 EP1753425 A4 EP 1753425A4
Authority
EP
European Patent Office
Prior art keywords
cancer
prevention
derivatives
treatment
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05764719A
Other languages
German (de)
French (fr)
Other versions
EP1753425A1 (en
Inventor
Suk-Chul Bae
Won-Jae Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIORUNX Co Ltd
Original Assignee
BIORUNX Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIORUNX Co Ltd filed Critical BIORUNX Co Ltd
Publication of EP1753425A1 publication Critical patent/EP1753425A1/en
Publication of EP1753425A4 publication Critical patent/EP1753425A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
EP05764719A 2004-05-12 2005-05-12 A therapeutic agent containing nicotinic acid or its derivatives as an effective ingredient for prevention and treatment of cancer Withdrawn EP1753425A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20040033323 2004-05-12
PCT/KR2005/001399 WO2005115388A1 (en) 2004-05-12 2005-05-12 A therapeutic agent containing nicotinic acid or its derivatives as an effective ingredient for prevention and treatment of cancer

Publications (2)

Publication Number Publication Date
EP1753425A1 EP1753425A1 (en) 2007-02-21
EP1753425A4 true EP1753425A4 (en) 2009-08-05

Family

ID=35450646

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05764719A Withdrawn EP1753425A4 (en) 2004-05-12 2005-05-12 A therapeutic agent containing nicotinic acid or its derivatives as an effective ingredient for prevention and treatment of cancer

Country Status (5)

Country Link
EP (1) EP1753425A4 (en)
JP (1) JP2007537246A (en)
KR (1) KR100775549B1 (en)
CN (1) CN1953748A (en)
WO (1) WO2005115388A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611847B2 (en) 2005-06-01 2009-11-03 Agency For Science, Technology And Research Method for identifying an intestinal phenotype
WO2011113300A1 (en) * 2010-03-15 2011-09-22 Yan Xiaojing Medicines for inhibiting toxicity or side effects caused by chemotherapeutic agents
AU2015335391B2 (en) * 2014-10-24 2018-06-21 Launx Biomedical Co., Ltd. Uses of duloxetine HCL medicament in preparing pharmaceutical composition for treatment of cancer
TWI648403B (en) * 2016-07-29 2019-01-21 臺北醫學大學 Diagnosis of gynecological tumors
US20210015788A1 (en) * 2018-03-13 2021-01-21 Nuchido Limited Compositions
CN108478573A (en) * 2018-03-30 2018-09-04 浙江中医药大学 A kind of 1- methylnicotinamides prepare prevent or treatment alcoholic fatty liver drug in application
CN108514561A (en) * 2018-05-21 2018-09-11 复旦大学 Application of the niacinamide in preventing and treating signet ring cell cancer
CN109364074B (en) * 2018-11-01 2021-05-07 重庆医科大学 Application of 6-aminonicotinamide as effective component in preparing medicament for treating hepatitis B
CN109942566B (en) * 2019-03-19 2021-07-23 厦门稀土材料研究所 Isonicotinic acid derivative and preparation method and application thereof
CN117281804A (en) * 2023-11-14 2023-12-26 北京大学 New application of nicotinic acid and new derivatives thereof in preparation of medicines for preventing or treating liver cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030705A1 (en) * 1997-12-16 1999-06-24 William Darwin Garner Reduction of uv induced skin cancer by topical amines
WO2002102981A2 (en) * 2001-06-15 2002-12-27 The Trustees Of Columbia University In The City Of New York SIR2α-BASED THERAPEUTIC AND PROPHYLACTIC METHODS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0534097A (en) * 1991-07-30 1993-02-09 Mitsubishi Heavy Ind Ltd Composite guidance device for missile

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030705A1 (en) * 1997-12-16 1999-06-24 William Darwin Garner Reduction of uv induced skin cancer by topical amines
WO2002102981A2 (en) * 2001-06-15 2002-12-27 The Trustees Of Columbia University In The City Of New York SIR2α-BASED THERAPEUTIC AND PROPHYLACTIC METHODS

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GOTOH H: "INHIBITORY EFFECTS OF NICOTINAMIDE ON THE GROWTH OF TRANSPLANTED MURINE BREAST CANCER AND URETHANE-INITIATED LUNG TUMORIGENESIS IN MICE", BITAMIN - VITAMINS, JOURNAL OF THE VITAMIN SOCIETY OF JAPAN, KYOTO, JP, vol. 67, no. 9, 1 January 1993 (1993-01-01), pages 469 - 479, XP008036628, ISSN: 0006-386X *
POUR P M ET AL: "MODIFICATION OF PANCREATIC CARCINOGENESIS IN THE HAMSTER MODEL. XV. PREVENTIVE EFFECT OF NICOTINAMIDE", JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIVERSITY PRESS, GB, vol. 73, no. 3, 1 January 1984 (1984-01-01), pages 767 - 770, XP008036629, ISSN: 0027-8874 *
See also references of WO2005115388A1 *

Also Published As

Publication number Publication date
JP2007537246A (en) 2007-12-20
WO2005115388A1 (en) 2005-12-08
KR100775549B1 (en) 2007-11-16
EP1753425A1 (en) 2007-02-21
KR20060047820A (en) 2006-05-18
CN1953748A (en) 2007-04-25

Similar Documents

Publication Publication Date Title
EP1753425A4 (en) A therapeutic agent containing nicotinic acid or its derivatives as an effective ingredient for prevention and treatment of cancer
EP1804761A4 (en) Compositions and methods for treatment of skin discoloration
IL179515A0 (en) Method of administering and using vegf inhibitors for the treatment of human cancer
IL177914A0 (en) Use of indazolecarboxamide derivatives for the preparation of a medicament that is intended for the treatment and prevention of paludism
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
EP1816996A4 (en) Methods and therapeutic compositions comprising plant extracts for the treatment of cancer
EP2099448A4 (en) Pharmaceutical composition for treatment and prevention of restenosis
EP1803460A4 (en) Composition and method for therapy or prevention of mental symptom
SI1765293T1 (en) Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
AU2003206946A8 (en) Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent
IL179210A0 (en) Heterocyclic derivatives for treatment of hyperlipidemia and related diseases
AU2003278775A8 (en) Porifera-based therapeutic compositions for treating and preventing skin diseases
IL197212A0 (en) Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
PL2063881T3 (en) A composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
TWI368521B (en) A spontaneous pharmaceutical composition for treatment and prevention of proliferative diseases,uses and preparation thereof
IL172018A0 (en) Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases
HK1111599A1 (en) Pharmaceutical compositions for the treatment of cellulite
PL1812797T3 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
EP1776100A4 (en) Treatment of cancer using benzoic acid derivatives
EP1765293A4 (en) Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
EP1967201A4 (en) Therapeutic agent for skin or skin repair-promoting agent comprising des-acylghrelin or derivative thereof as active ingredient
EP1551456A4 (en) Pharmaceutical composition for prevention and treatment of kidney diseases
EP1669085A4 (en) Medical agent for prevention and/or treatment of alzheimer disease
PL354698A1 (en) Pharmaceutical compound for prevention or treatment of self-immunization based diseases
AU2003266621A8 (en) Medicinal composition for treatment for or prevention of visceral pain

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KIM, WON-JAE

Inventor name: BAE, SUK-CHUL

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090702

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091001